Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease

1993 ◽  
Vol 5 (3) ◽  
pp. 193-202 ◽  
Author(s):  
E. H. Heinonen ◽  
M. Savijärvi ◽  
M. Kotila ◽  
A. Hajba ◽  
M. Scheinin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Metabolites ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

Multifunctional 3-Schiff base-4-hydroxycoumarin derivatives with monoamine oxidase inhibition, anti-β-amyloid aggregation, metal chelation, antioxidant and neuroprotection properties against Alzheimer's disease

RSC Advances ◽  
2015 ◽  
Vol 5 (86) ◽  
pp. 70395-70409 ◽  
Author(s):  
Zhi-Min Wang ◽  
Sai-Sai Xie ◽  
Xue-Mei Li ◽  
Jia-Jia Wu ◽  
Xiao-Bing Wang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Schiff Base ◽  
Monoamine Oxidase ◽  
Metal Chelation ◽  
Amyloid Aggregation ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition ◽  
Multifunctional Agents ◽  
Β Amyloid

These 3-Schiff base-4-hydroxycoumarin derivatives were multifunctional agents with monoamine oxidase inhibition, anti-β-amyloid aggregation, metal chelation, antioxidant and neuroprotection properties against Alzheimer's disease.

Multitarget-directed resveratrol derivatives: anti-cholinesterases, anti-β-amyloid aggregation and monoamine oxidase inhibition properties against Alzheimer's disease

MedChemComm ◽  
2014 ◽  
Vol 5 (5) ◽  
pp. 609-616 ◽  
Author(s):  
Long-Fei Pan ◽  
Xiao-Bing Wang ◽  
Sai-Sai Xie ◽  
Su-Yi Li ◽  
Ling-Yi Kong
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoamine Oxidase ◽  
Amyloid Aggregation ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition ◽  
Β Amyloid ◽  
Resveratrol Derivatives

Resveratrol derivatives were designed and synthesized as multitarget-directed agents for treating AD, and 6r was a balanced inhibitor toward all the tested targets.

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline

1989 ◽  
Vol 46 (5) ◽  
pp. 528-536 ◽  
Author(s):  
Rainer Schulz ◽  
Karl-Heinz Antonin ◽  
Edgar Hoffmann ◽  
Maria Jedrychowski ◽  
Eric Nilsson ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease

1987 ◽  
Vol 91 (3) ◽  
pp. 293-296 ◽  
Author(s):  
T. Sunderland ◽  
P. N. Tariot ◽  
R. M. Cohen ◽  
P. A. Newhouse ◽  
A. M. Mellow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoamine Metabolites ◽  
Dose Dependent

scholarly journals Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes

2016 ◽  
Vol 14 (2) ◽  
pp. 163-165 ◽  
Author(s):  
Hamlin Emory ◽  
Neptune Mizrahi
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Combined Treatment ◽  
Insulin Regimen ◽  
Imaging Data ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

We present clinical, electroencephalographic and low-resolution electromagnetic tomography data that support combined treatment with insulin and a monoamine oxidase inhibitor in a patient with type 1 diabetes. We suggest that brain imaging data can identify a subgroup of patients who are likely to benefit from an insulin regimen and monoamine oxidase inhibition to improve glycaemic control, cardiovascular function, normalize the circadian rhythm and restore perception of glycaemic awareness.

Sign in / Sign up

Export Citation Format

Share Document